复发性卵巢癌女性在二线化疗前的血小板增多症和贫血
Thrombocytosis and anaemia in women with recurrent ovarian cancer prior to a second-line chemotherapy.
作者信息
Nather Andreas, Mayerhofer Klaus, Grimm Christoph, Hefler Lukas, Leodolter Sepp, Obermair Andreas, Joura Elmar A
机构信息
Department of Gynecology and Obstetrics, Vienna University Medical School, A-1090 Vienna, Währinger Gürtel 18-20, Austria.
出版信息
Anticancer Res. 2003 May-Jun;23(3C):2991-4.
BACKGROUND
To investigate the incidence and the prognostic value of platelet count and serum haemoglobin (Hb) in patients with recurrent ovarian cancer prior to second-line chemotherapy.
MATERIALS AND METHODS
Clinical records were reviewed for 31 patients with recurrent ovarian cancer. Survival analysis was evaluated by univariate (Kaplan-Meier product limit method and log-rank test) analysis. We analysed the results for the overall survival. Anaemia and thrombocytosis were defined as a serum Hb level < 12 g/dl and as platelet count > 300,000/microL, respectively.
RESULTS
Thrombocytosis and tumour anaemia were present in 55% and 42% of the patients, respectively. Tumour anaemia was of no prognostic value with respect to overall survival in our series. In patients with thrombocytosis, the median survival rate was reduced (p = 0.05).
CONCLUSION
Our data suggest that a platelet count > 300,000/microL appears to be an adverse prognostic parameter in patients with recurrent ovarian cancer prior to a second-line chemotherapy.
背景
探讨复发性卵巢癌患者在二线化疗前血小板计数和血清血红蛋白（Hb）的发生率及预后价值。
材料与方法
回顾31例复发性卵巢癌患者的临床记录。采用单因素分析（Kaplan-Meier乘积限界法和对数秩检验）评估生存分析。我们分析了总生存结果。贫血和血小板增多症分别定义为血清Hb水平<12 g/dl和血小板计数>300,000/μL。
结果
分别有55%和42%的患者存在血小板增多症和肿瘤性贫血。在我们的系列研究中，肿瘤性贫血对总生存无预后价值。血小板增多症患者的中位生存率降低（p = 0.05）。
结论
我们的数据表明，血小板计数>300,000/μL似乎是复发性卵巢癌患者二线化疗前的一个不良预后参数。
Zotero 插件